Gabapentin Capsule
Product Images NDC 70518-1469

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-1469). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 400mg 70518 1469 00

Gabapentin is a medication that comes in a capsule form of 400mg strength. The package contains 30 capsules and should only be used as prescribed. The manufacturer is Ascend Labs with the source parallel import of NDC 67877-0224-05. The medication should be stored at a temperature between 20-25°C. The prescription is repackaged by RemedyRepack Ine located in Indiana, PA. Additional information can be found in the package insert.*

FDA Label Image

Gabapentin 400mg 70518 1469 01

FDA Label Image

Gabapentin 400mg 70518 1469 02

Gabapentin is a medication in capsule form with a strength of 400mg, and the quantity is 180. It is repackaged by RemedyRepack Inc in Indiana, PA, and the manufacturer is Ascend Labs, LLC, located in Montvale, NJ. The medication should be stored at a temperature range of 20-25°C (88-77°F), with excursions allowed between 15-30°C (59-86°F) and should be kept out of reach of children. It requires a prescription and the source NDC is 67877-0224-05 while the RX only NDC is 70518-1469-02. It is advisable to refer to the package insert for directions on how to use it, and it has an expiry date and a LOT#.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

FDA Label Image

Gabapentin Fig1

This is a description of a clinical trial that had a four-week dose titration period followed by a four-week fixed-dose period. The placebo was compared to Gabapentin, which was given at a maximum dosage of 3600 mg/day. The only numerical data provided is the mean pain score, which was not included, possibly due to errors.*

FDA Label Image

Gabapentin Fig2

This is a table that shows mean pain scores for different treatment methods over a period of 4 weeks. The treatments include a placebo, 1800 mg/day and 2400 mg/day of Gabapentin. The rows show the baseline and each week of the study.*

FDA Label Image

Gabapentin Fig3

The text describes a figure labeled "Figure 3" that shows the proportion of responders in controlled studies for post-herpetic neuralgia (PHN) at endpoint, with percentages ranging from 100% to 10%. The data for the different studies is presented in a table, with headings for each column including study, GBP (presumably a medication), PBO (placebo), and response rates. There are also notes below the table indicating statistical significance (p < 0.001) for some of the response rates.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.